Publications by authors named "C R Divgi"
Despite the inclusion of multiple agents within the prostate cancer treatment landscape, new treatment options are needed to address the unmet need for patients with metastatic castration-resistant prostate cancer (mCRPC). Although prostate-specific membrane antigen is the only cell-surface target to yield clinical benefit in men with advanced prostate cancer, additional targets may further advance targeted immune, cytotoxic, radiopharmaceutical, and other tumor-directed therapies for these patients. Human kallikrein 2 (hK2) is a novel prostate-specific target with little to no expression in nonprostate tissues.
View Article and Find Full Text PDFBackground: FDG PET/CT is a tool for assessing response to therapy in various cancers, and may provide an earlier biomarker of clinical response. We developed a novel semi-automated approach for analyzing FDG PET/CT images in patients with multiple myeloma (MM) to standardize FDG PET application.
Methods: Patients (n = 8) with relapsed/refractory MM from the Phase 2 study (NCT02899052) of venetoclax plus carfilzomib and dexamethasone underwent FDG PET/CT at baseline and up to two timepoints during treatment.
A threshold-based method to predict thyroid nodules on scintigraphy scans.
Biomed Phys Eng Express
January 2020
Article Synopsis
- Nuclear Medicine imaging is crucial for evaluating thyroid abnormalities, distinguishing between high-risk 'cold' nodules and low-risk 'hot' nodules based on radiotracer uptake patterns.
- The quality of nuclear images often results in subtle density changes that may be overlooked, but a computer-aided detection (CAD) system using pixel density thresholds can enhance the identification of nodules.
- In tests with 22 nodules, both 'hot' and 'cold', the CAD approach showed strong alignment with expert radiologists' assessments, indicating its potential effectiveness in improving diagnostic accuracy.
Radiopharmaceutical therapy (RPT) continues to demonstrate tremendous potential in improving the therapeutic gains in radiation therapy by specifically delivering radiation to tumors that can be well assessed in terms of dosimetry and imaging. Dosimetry in external beam radiation therapy is standard practice. This is not the case, however, in RPT.
View Article and Find Full Text PDFArticle Synopsis
- Estrogen receptor (ER) status, determined via immunohistochemistry (IHC), is critical for guiding breast cancer treatment, while F-FES PET provides a non-invasive way to assess ER function in lesions.
- A meta-analysis was conducted to compare F-FES PET and tissue assay results for determining ER status, which included a total of 327 lesions and highlighted the sensitivity and specificity of F-FES PET imaging.
- Findings suggest that F-FES PET is a promising alternative or complement to traditional tissue biopsies for assessing ER status, potentially leading to better treatment outcomes for patients with ER-positive metastatic breast cancer.